Annexin Pharmaceuticals completes enrollment in NEXUS trial of vanexin
Bitget2026/10/22 06:29- Annexin Pharmaceuticals completed enrollment in its NEXUS vanexin study, recruiting 12 patients: nine with retinal vein occlusion and three with diabetic retinopathy.
- Results are due in November 2026 for diabetic retinopathy patients and December 2026 for the expanded retinal vein occlusion cohort.
- The study will finish in the first quarter of 2027, with topline results expected by quarter-end.
- An FDA meeting expected in early 2027 will address Phase 2b and Phase 3 study design, including vanexin treatment following anti-VEGF therapy.
- Global or regional licensing discussions aim to secure a Phase 2b partner; timing for a potential agreement remains uncertain.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
HBAR Price Eyes $0.155 as Traders Watch Key Recovery Levels
Microsoft Beats Nvidia for the First Time Since 2025: So Why Is MSFT Stock Falling?
Gunnison hits rich copper and zinc in Arizona
EIA expects Brent crude spot prices to remain at $100 per barrel for the rest of the year and raises the average price forecasts for this year and next.
The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.
Crypto prices
More
